Breaking

● GLP-1 trial shows 34% reduction in cardiovascular events over 5 years ● Senolytics drug enters Phase III — first human trial results expected Q1 2027 ● FDA fast-tracks CRISPR base-editing therapy for sickle cell disease ● Longevity biotech index up 12% YTD as institutional capital accelerates ● AI diagnostic platform achieves 97.2% accuracy in early-stage pancreatic cancer detection ● Harvard study links CGM use to 23% lower all-cause mortality in non-diabetics● GLP-1 trial shows 34% reduction in cardiovascular events over 5 years ● Senolytics drug enters Phase III — first human trial results expected Q1 2027 ● FDA fast-tracks CRISPR base-editing therapy for sickle cell disease ● Longevity biotech index up 12% YTD as institutional capital accelerates ● AI diagnostic platform achieves 97.2% accuracy in early-stage pancreatic cancer detection ● Harvard study links CGM use to 23% lower all-cause mortality in non-diabetics